AAPL299.43+2.42 (+0.81%) ▲|ABBV234.34+4.33 (+1.88%) ▲|ABT90.27+2.44 (+2.77%) ▲|ACN126.48+1.65 (+1.32%) ▲|ADBE196.81+1.91 (+0.98%) ▲|AMAT582.66-57.52 (-8.99%) ▼|AMD521.69-29.94 (-5.43%) ▼|AMGN347.21+2.49 (+0.72%) ▲|AMT176.94+0.51 (+0.29%) ▲|AMZN234.09+1.30 (+0.56%) ▲|AVGO380.98-11.16 (-2.84%) ▼|AXP337.82-0.26 (-0.08%) ▼|BA218.75-2.08 (-0.94%) ▼|BAC57.84+0.47 (+0.82%) ▲|BKNG167.94+0.17 (+0.10%) ▲|BLK1,030.89-20.85 (-1.98%) ▼|BMY55.38+0.68 (+1.24%) ▲|BNY147.98+1.54 (+1.05%) ▲|BRK-B493.71+5.02 (+1.03%) ▲|C145.82+0.15 (+0.10%) ▲|CAT986.47-35.82 (-3.50%) ▼|CL90.92+2.25 (+2.54%) ▲|CMCSA22.78+0.46 (+2.04%) ▲|COF199.94-0.76 (-0.38%) ▼|COP110.10+0.40 (+0.36%) ▲|COST961.91+10.56 (+1.11%) ▲|CRM152.59+2.47 (+1.65%) ▲|CSCO119.59-1.94 (-1.60%) ▼|CVS101.82+0.52 (+0.51%) ▲|CVX175.65+0.59 (+0.34%) ▲|DE598.23-0.36 (-0.06%) ▼|DHR178.17-0.03 (-0.01%) ▼|DIS103.11+0.66 (+0.64%) ▲|DUK125.20+1.68 (+1.36%) ▲|EMR144.49-5.72 (-3.81%) ▼|FDX322.87-5.91 (-1.80%) ▼|GD348.01+4.65 (+1.35%) ▲|GE357.11+1.99 (+0.56%) ▲|GEV1,051.83-75.76 (-6.72%) ▼|GILD126.09+1.22 (+0.97%) ▲|GM79.48-0.96 (-1.19%) ▼|GOOG346.16-2.62 (-0.75%) ▼|GOOGL346.70-2.86 (-0.82%) ▼|GS1,099.85-6.52 (-0.59%) ▼|HD327.00+0.38 (+0.12%) ▲|HON224.81-3.31 (-1.45%) ▼|IBM265.24+13.02 (+5.16%) ▲|INTC135.87-5.07 (-3.60%) ▼|INTU260.03+2.26 (+0.87%) ▲|ISRG399.69-3.27 (-0.81%) ▼|JNJ235.47+4.18 (+1.81%) ▲|JPM334.79+3.31 (+1.00%) ▲|KO80.15+0.62 (+0.78%) ▲|LIN518.02+1.31 (+0.25%) ▲|LLY1,100.45-1.63 (-0.15%) ▼|LMT500.55+6.95 (+1.41%) ▲|LOW214.97+0.57 (+0.27%) ▲|LRCX368.16-41.39 (-10.11%) ▼|MA487.83+3.74 (+0.77%) ▲|MCD272.33+2.23 (+0.82%) ▲|MDLZ60.76+1.25 (+2.09%) ▲|MDT80.40+1.13 (+1.43%) ▲|META564.13+0.28 (+0.05%) ▲|MMM162.64-0.58 (-0.36%) ▼|MO71.09+1.58 (+2.27%) ▲|MRK118.26+2.78 (+2.41%) ▲|MS226.68-0.42 (-0.18%) ▼|MSFT374.62+7.28 (+1.98%) ▲|MU1,084.53-126.85 (-10.47%) ▼|NEE86.68+0.60 (+0.69%) ▲|NFLX72.69-0.19 (-0.26%) ▼|NKE42.42-0.77 (-1.78%) ▼|NOW96.71+3.70 (+3.98%) ▲|NVDA200.95-7.71 (-3.69%) ▼|ORCL170.02-5.06 (-2.89%) ▼|PEP141.65+0.94 (+0.67%) ▲|PFE24.87-0.21 (-0.84%) ▼|PG150.78+3.10 (+2.10%) ▲|PLTR118.58-0.92 (-0.77%) ▼|PM178.41+5.24 (+3.02%) ▲|QCOM199.77-22.13 (-9.97%) ▼|RTX183.96+2.13 (+1.17%) ▲|SBUX99.96-0.19 (-0.19%) ▼|SCHW92.83+0.80 (+0.87%) ▲|SO94.82+1.39 (+1.48%) ▲|SPG216.89+2.32 (+1.08%) ▲|T22.61+0.51 (+2.29%) ▲|TMO464.96+0.95 (+0.20%) ▲|TMUS182.64+2.58 (+1.43%) ▲|TSLA384.84-20.21 (-4.99%) ▼|TXN304.90-27.38 (-8.24%) ▼|UBER70.45-0.99 (-1.38%) ▼|UNH404.19-2.50 (-0.61%) ▼|UNP261.09+1.18 (+0.45%) ▲|UPS106.43-0.81 (-0.76%) ▼|USB59.60+0.92 (+1.57%) ▲|V330.90+4.30 (+1.32%) ▲|VZ46.09+0.73 (+1.60%) ▲|WFC84.02+0.18 (+0.21%) ▲|WMT119.63+2.45 (+2.09%) ▲|XOM139.47+1.00 (+0.72%) ▲|AAPL299.43+2.42 (+0.81%) ▲|ABBV234.34+4.33 (+1.88%) ▲|ABT90.27+2.44 (+2.77%) ▲|ACN126.48+1.65 (+1.32%) ▲|ADBE196.81+1.91 (+0.98%) ▲|AMAT582.66-57.52 (-8.99%) ▼|AMD521.69-29.94 (-5.43%) ▼|AMGN347.21+2.49 (+0.72%) ▲|AMT176.94+0.51 (+0.29%) ▲|AMZN234.09+1.30 (+0.56%) ▲|AVGO380.98-11.16 (-2.84%) ▼|AXP337.82-0.26 (-0.08%) ▼|BA218.75-2.08 (-0.94%) ▼|BAC57.84+0.47 (+0.82%) ▲|BKNG167.94+0.17 (+0.10%) ▲|BLK1,030.89-20.85 (-1.98%) ▼|BMY55.38+0.68 (+1.24%) ▲|BNY147.98+1.54 (+1.05%) ▲|BRK-B493.71+5.02 (+1.03%) ▲|C145.82+0.15 (+0.10%) ▲|CAT986.47-35.82 (-3.50%) ▼|CL90.92+2.25 (+2.54%) ▲|CMCSA22.78+0.46 (+2.04%) ▲|COF199.94-0.76 (-0.38%) ▼|COP110.10+0.40 (+0.36%) ▲|COST961.91+10.56 (+1.11%) ▲|CRM152.59+2.47 (+1.65%) ▲|CSCO119.59-1.94 (-1.60%) ▼|CVS101.82+0.52 (+0.51%) ▲|CVX175.65+0.59 (+0.34%) ▲|DE598.23-0.36 (-0.06%) ▼|DHR178.17-0.03 (-0.01%) ▼|DIS103.11+0.66 (+0.64%) ▲|DUK125.20+1.68 (+1.36%) ▲|EMR144.49-5.72 (-3.81%) ▼|FDX322.87-5.91 (-1.80%) ▼|GD348.01+4.65 (+1.35%) ▲|GE357.11+1.99 (+0.56%) ▲|GEV1,051.83-75.76 (-6.72%) ▼|GILD126.09+1.22 (+0.97%) ▲|GM79.48-0.96 (-1.19%) ▼|GOOG346.16-2.62 (-0.75%) ▼|GOOGL346.70-2.86 (-0.82%) ▼|GS1,099.85-6.52 (-0.59%) ▼|HD327.00+0.38 (+0.12%) ▲|HON224.81-3.31 (-1.45%) ▼|IBM265.24+13.02 (+5.16%) ▲|INTC135.87-5.07 (-3.60%) ▼|INTU260.03+2.26 (+0.87%) ▲|ISRG399.69-3.27 (-0.81%) ▼|JNJ235.47+4.18 (+1.81%) ▲|JPM334.79+3.31 (+1.00%) ▲|KO80.15+0.62 (+0.78%) ▲|LIN518.02+1.31 (+0.25%) ▲|LLY1,100.45-1.63 (-0.15%) ▼|LMT500.55+6.95 (+1.41%) ▲|LOW214.97+0.57 (+0.27%) ▲|LRCX368.16-41.39 (-10.11%) ▼|MA487.83+3.74 (+0.77%) ▲|MCD272.33+2.23 (+0.82%) ▲|MDLZ60.76+1.25 (+2.09%) ▲|MDT80.40+1.13 (+1.43%) ▲|META564.13+0.28 (+0.05%) ▲|MMM162.64-0.58 (-0.36%) ▼|MO71.09+1.58 (+2.27%) ▲|MRK118.26+2.78 (+2.41%) ▲|MS226.68-0.42 (-0.18%) ▼|MSFT374.62+7.28 (+1.98%) ▲|MU1,084.53-126.85 (-10.47%) ▼|NEE86.68+0.60 (+0.69%) ▲|NFLX72.69-0.19 (-0.26%) ▼|NKE42.42-0.77 (-1.78%) ▼|NOW96.71+3.70 (+3.98%) ▲|NVDA200.95-7.71 (-3.69%) ▼|ORCL170.02-5.06 (-2.89%) ▼|PEP141.65+0.94 (+0.67%) ▲|PFE24.87-0.21 (-0.84%) ▼|PG150.78+3.10 (+2.10%) ▲|PLTR118.58-0.92 (-0.77%) ▼|PM178.41+5.24 (+3.02%) ▲|QCOM199.77-22.13 (-9.97%) ▼|RTX183.96+2.13 (+1.17%) ▲|SBUX99.96-0.19 (-0.19%) ▼|SCHW92.83+0.80 (+0.87%) ▲|SO94.82+1.39 (+1.48%) ▲|SPG216.89+2.32 (+1.08%) ▲|T22.61+0.51 (+2.29%) ▲|TMO464.96+0.95 (+0.20%) ▲|TMUS182.64+2.58 (+1.43%) ▲|TSLA384.84-20.21 (-4.99%) ▼|TXN304.90-27.38 (-8.24%) ▼|UBER70.45-0.99 (-1.38%) ▼|UNH404.19-2.50 (-0.61%) ▼|UNP261.09+1.18 (+0.45%) ▲|UPS106.43-0.81 (-0.76%) ▼|USB59.60+0.92 (+1.57%) ▲|V330.90+4.30 (+1.32%) ▲|VZ46.09+0.73 (+1.60%) ▲|WFC84.02+0.18 (+0.21%) ▲|WMT119.63+2.45 (+2.09%) ▲|XOM139.47+1.00 (+0.72%) ▲|
20.6 C
New York
Tuesday, June 23, 2026

Tag: treatments

newssourceFORcompanyinformationcontent1marketreleases

Xpres Spa Named One of Yelp’s Most Loved Airport Brands

Amid industry recognition, XWELL expands its wellness footprint, bringing self-care beyond the terminal with new locations and partnerships 
Amid industry recognition, XWELL expands its wellness footprint, bringing self-care beyond the terminal with new locations and partnerships

Allarity Therapeutics Announces Dosing of Second Patient in New Phase 2 Trial of Stenoparib in Advanced Ovarian Cancer

        

UCB announces positive results from GEMZ Phase 3 study of fenfluramine in CDKL5 deficiency disorder

Phase 3 study met primary and most key secondary clinical endpointsThis marks the third developmental and epileptic encephalopathies (DEE) population for fenfluramine with positive phase...

MGI ANNOUNCES PARTNERSHIP WITH NEGEDIA: ENHANCE GENOMIC SEQUENCING TECHNOLOGIES AT THE SERVICE OF SCIENTIFIC RESEARCH AND PRECISION MEDICINE IN ITALY

In the study of rare diseases and precision medicine, understanding gene expression in the spatial context of tissues is essential. High-throughput sequencing and STOmics technology will...

Peer-Reviewed Study in Nature Scientific Reports Demonstrates Non-Invasive Fat Reduction Using Alma’s Energy-Based Technology

CAESAREA, Israel, June 27, 2025 /PRNewswire/ -- A newly published, peer-reviewed study in Nature Scientific Reports, part of the prestigious Nature Portfolio, presents compelling clinical...

Peer-Reviewed Study in Nature Scientific Reports Demonstrates Non-Invasive Fat Reduction Using Alma’s Energy-Based Technology

CAESAREA, Israel, June 27, 2025 /PRNewswire/ -- A newly published, peer-reviewed study in Nature Scientific Reports, part of the prestigious Nature Portfolio, presents compelling clinical...

WuXi AppTec Nantong Site Receives 2025 Architizer A+Award for Its Unique Blend of Technology and Humanity

SHANGHAI, June 26, 2025 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies...

Earth Science Tech, Inc. Reports Fiscal Year-End Results for March 31, 2025, with Revenue Exceeding $33.1 Million and Net Profit of $3.2 Million

Miami, FL, June 26, 2025 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC: ETST) (“ETST” or “Company”), a strategic holding company, focused on value creation through the acquisition, operational optimization, and management of its operating businesses, today shares its financial results for the year ended March 31, 2025.

Prism Pain and Wellness Offering Novel Brain Stimulation to Treat Depression and Optimize Mental Health

ENGLEWOOD, Colo., June 26, 2025 /PRNewswire/ -- The pinnacle of medication-free wellness is now available for those struggling with depression, anxiety and mental fog....

Pendopharm® and KalVista® Partner to Bring First Oral On-Demand HAE Treatment to Canada

MONTREAL, June 26, 2025 /CNW/ - Pendopharm®, a division of Pharmascience Inc., has entered into an exclusive distribution agreement with KalVista Pharmaceuticals, Inc. (NASDAQ:...

Kane Biotech Announces Conversion of Demand Loan from Insider into an Unsecured Convertible Debenture and Annual General Meeting Voting Results

Not for distribution to U.S. news wire services or dissemination in the United States

Miracle Made Silver-Infused Sheets Gain Momentum as Clean Sleep Innovation Expands Across U.S. Market

Silver-Infused Bedding Innovation Gains Ground as Miracle Made® Expands U.S. Reach With Bacteria-Resistant, Temperature-Regulating Sheets Supporting Modern Sleep Hygiene 
Silver-Infused Bedding Innovation Gains Ground as Miracle Made® Expands U.S. Reach With Bacteria-Resistant, Temperature-Regulating Sheets Supporting Modern Sleep Hygiene

Global Cancer Immunotherapy Market Projected to Reach $247 Billion by 2029, Driven by 11.4% CAGR

"Harnessing the Power of the Immune System: How Cancer Immunotherapy and Oncolytic Virology Are Reshaping the Future of Oncology in a Digitally Driven Era" BOSTON,...

Everest Medicines to Host Virtual Nephrology-Focused KOL Event on June 30, 2025

SHANGHAI, June 26, 2025 (GLOBE NEWSWIRE) -- Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that it will host a virtual nephrology-focused key opinion leader (KOL) event on Monday, June 30, 2025 at 8:00 AM ET. For English speakers, please click here to register. For individuals preferring instant Chinese translation, please click here.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsTreatments

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers